US Patent Issued to Brookhaven Lab, BioSet
Brookhaven Science Associates, which operates and manages the US Department of Energy’s Brookhaven National Laboratory, and Biosurface Engineering Technologies Inc. (BioSet) have been issued a US patent for a synthetic peptide called B2A. A medical device called Amplex has been developed that incorporates B2A osteoinductive growth factor with an ultrahigh-grade ceramic bone substitute for use in surgery. The FDA has approved a pilot study of 22 patients by BioSet to evaluate the safety and preliminary efficacy of the device.
LATEST NEWS
- Quantinuum Launches 56-Qubit Quantum Computer: Week in Brief: 6/7/2024
Jun 7, 2024
- Atom Computing Lands Investment, Expands Overseas
Jun 7, 2024
- Optogenetic Stimulation Enables Fatigue-Resistant Muscle Control
Jun 6, 2024
- Quandela Launches Pilot Line for Qubit Devices
Jun 6, 2024
- Lattice Semiconductor Adds Interim CEO
Jun 6, 2024
- On-Chip Microcomb Laser Provides Greater Control
Jun 5, 2024
- Flexible, Stretchable Device Addresses Tuning Limitations in Structural Color
Jun 5, 2024
- Fusion Startup Xcimer Raises $100M, Plans Laser Prototype
Jun 4, 2024